Warning: The NCBI web site requires JavaScript to function. more...
Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports.
Moore RA, Derry S, McQuay HJ.
Arthritis Res Ther. 2008;10(3):R53. Epub 2008 May 8.
Related citations
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.
Moore RA, Derry S, Makinson GT, McQuay HJ.
Arthritis Res Ther. 2005;7(3):R644-65. Epub 2005 Mar 24. Review. Erratum in: Arthritis Res Ther. 2006;8(1):401.
Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.
Curr Med Res Opin. 2004 Dec;20(12):1899-908.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.
Curr Med Res Opin. 2006 Dec;22(12):2365-74.
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee.
Lancet. 2006 Nov 18;368(9549):1771-81.
Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, Reicin AS.
Clin Ther. 2004 Jan;26(1):70-83.
Single dose oral etoricoxib for acute postoperative pain in adults.
Clarke R, Derry S, Moore RA, McQuay HJ.
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004309. Review.
Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
Edwards JE, McQuay HJ, Moore RA.
Pain. 2004 Oct;111(3):286-96. Review.
Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
[No authors listed]
Prescrire Int. 2007 Dec;16(92):223-7.
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP; MEDAL Steering Committee.
Lancet. 2007 Feb 10;369(9560):465-73.
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Cannon CP, Curtis SP, Bolognese JA, Laine L; MEDAL Steering Committee.
Am Heart J. 2006 Aug;152(2):237-45.
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, Zhao PL, Rodgers DB, McCormick CL, Lee M, Lines CR, Gertz BJ; Etoricoxib Rheumatoid Arthritis Study Group.
BMC Fam Pract. 2002 May 22;3:10.
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.
Ann Rheum Dis. 2008 Mar;67(3):315-22. Epub 2007 Oct 27. Erratum in: Ann Rheum Dis.2008 May;67(5):732.
Etoricoxib: a highly selective COX-2 inhibitor.
Martina SD, Vesta KS, Ripley TL.
Ann Pharmacother. 2005 May;39(5):854-62. Epub 2005 Apr 12. Review.
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Patrignani P, Capone ML, Tacconelli S.
Expert Opin Pharmacother. 2003 Feb;4(2):265-84. Review.
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS.
Curr Med Res Opin. 2005 May;21(5):715-22.
Etoricoxib.
Cochrane DJ, Jarvis B, Keating GM.
Drugs. 2002;62(18):2637-51; discussion 2652-3. Review.
Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
Croom KF, Siddiqui MA.
Drugs. 2009 Jul 30;69(11):1513-32. doi: 10.2165/00003495-200969110-00008. Review.
Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.
Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR, Geba GP; Etoricoxib Protocol 042 Study Group.
J Pain. 2003 Aug;4(6):307-15.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on